Vazyme(SH:688105) Xin Lang Cai Jing·2025-10-27 05:20Core Points - The stock price of NuoVasive increased by 2.05% on October 27, reaching 22.92 CNY per share, with a total market capitalization of 9.116 billion CNY [1] - The company has seen a year-to-date stock price increase of 4.09%, with a 4.37% rise over the last five trading days [1] Company Overview - NuoVasive, established on March 16, 2012, and listed on November 15, 2021, is a biotechnology company based in Nanjing, Jiangsu Province, focusing on the research and development of functional proteins and high molecular organic materials [1] - The company's main business revenue composition includes: 81.86% from biological reagents, 9.99% from diagnostic reagents, 3.15% from consumables, 2.96% from equipment, 1.85% from technical services, and 0.18% from other sources [1] Financial Performance - For the first half of 2025, NuoVasive reported a revenue of 606 million CNY, a year-on-year decrease of 6.63%, and a net profit attributable to shareholders of 3.1294 million CNY, down 80.63% year-on-year [2] - The company has distributed a total of 731 million CNY in dividends since its A-share listing, with 611 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, the number of shareholders for NuoVasive was 8,596, an increase of 2.37% from the previous period, with an average of 46,269 circulating shares per shareholder, a decrease of 2.31% [2]